secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001999371-26-009289
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix presents TNX-4800 Phase 1 data; plans adaptive Phase 2 field study for Lyme disease prevention in H1 2027
--------------------------------------------------------------------------------

- Phase 1 data of TNX-4800 (anti-OspA mAb) for Lyme disease presented at Ticks and Tickborne Diseases Symposium.
- Planned adaptive Phase 2 field study: two-dose SC regimen, primary endpoint 6-month protection; start H1 2027 pending FDA agreement.
- FDA Type C meeting scheduled early Q3 2026 to discuss Phase 2 study design.
- Each fixed subcutaneous dose expected to provide exposure comparable to 5 mg/kg dose in Phase 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126009289/0001999371-26-009289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126009289/tnxp_8k-0422926.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-009289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer